This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease. Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of
ASBM Whitepaper to Examine Impact of Medicare Drug Price-Setting on Drug Development, Patient Access The Journal of the Generics and Biosimilars Initiative (GaBI) is currently finalizing a whitepaper based on the July 26th webinar hosted by ASBM and GaBI entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines.
PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients. Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen P
On November 6, 2023, the Centers for Medicare and Medicaid Services (CMS) announced a proposed Rule that would permit Medicare Part D plan sponsors to substitute non-interchangeable biosimilars in place of the biologic medicines now used to treat many chronic conditions such as rheumatoid arthritis, Crohn’s disease and cancer. The policy change represents a stark departure from the perspectives of the U.S. medical community and patient advocacy organizations, a decade of state-level policymaking
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending… The post AI-Driven Strategies: Pharma’s Answer to Patent Expirations appeared first on DrugPatentWatch - Make Better Decisions.
In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending… The post AI-Driven Strategies: Pharma’s Answer to Patent Expirations appeared first on DrugPatentWatch - Make Better Decisions.
Zydus Lifesciences was able to successfully launch its homegrown NCE drugs Oxemia (desidustat) and Lipaglyn (saroglitazor) in the Indian market. It also partnered with Sun Pharma and Lupin to co-market desidustat and saroglitazar, respectively, in the Indian market. These partnerships will help improve the market penetration of these drugs in India, says GlobalData.
This chart shows the pharmaceutical companies with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.
Early clinical trial results are the first for a base editing treatment and show Verve’s therapy can substantially lower cholesterol levels by editing the genes of liver cells.
A clinical stage pipeline asset for the company , LP-310 is intended to be indicated for inflammatory diseases of the oral cavity, including oral lichen planus and oral GvHD. Earlier, LP-10 received ODD from the FDA, thereby making LP-310 the second of the company’s leading product candidates to receive this designation. LP-310 liposomal tacrolimus is an oral rinse formulation of the company’s lead drug candidate, LP-10.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Acetylcysteine is the generic ingredient in seven branded drugs marketed by Cumberland Pharms, Aspen, Eugia Pharma, Exela Pharma, Fresenius Kabi Usa, Indoco, Rising, Sagent Pharms Inc, Steriscience, Zydus Pharms, Alvogen,… The post New tentative approval for Rising drug acetylcysteine appeared first on DrugPatentWatch - Make Better Decisions.
The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.
Annual Drug Patent Expirations for SKYLA Skyla is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are six patents… The post New patent expiration for Bayer Hlthcare drug SKYLA appeared first on DrugPatentWatch - Make Better Decisions.
In this episode, I’ll discuss haloperidol for ICU delirium. Episode 869: Three Recent Studies About Haloperidol and ICU Delirium Subscribe on iTunes , Android , or Stitcher Despite efforts to reduce the incidence of ICU delirium with light sedation techniques, many patients still end up with delirium during their stay in the ICU. Some of these patients develop agitated delirium that requires treatment so the patient does not harm themselves or staff caring for them.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Annual Drug Patent Expirations for KYLEENA Kyleena is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are six patents… The post New patent expiration for Bayer Hlthcare drug KYLEENA appeared first on DrugPatentWatch - Make Better Decisions.
In this episode, I’ll discuss haloperidol for ICU delirium. Episode 869: Three Recent Studies About Haloperidol and ICU Delirium Subscribe on iTunes , Android , or Stitcher Despite efforts to reduce the incidence of ICU delirium with light sedation techniques, many patients still end up with delirium during their stay in the ICU. Some of these patients develop agitated delirium that requires treatment so the patient does not harm themselves or staff caring for them.
AMRIX (cyclobenzaprine hydrochloride) Teva pharms intl Patent: 7,829,121 Expiration: Nov 14, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… The post Drug Patent Expirations for the Week of November 12, 2023 appeared first on DrugPatentWatch - Make Better Decisions.
The Patented Medicine Prices Review Board ( PMPRB ) has released a scoping paper on themes and questions to develop new price review Guidelines. The scoping paper also includes information on how stakeholders can participate in the consultation. The deadline for written submissions addressing the scoping paper is December 20, 2023. Background The PMPRB has not had a full set of Guidelines since July 1, 2022, when amendments to the Patented Medicines Regulations came into force implementing a
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
In this case scenario, I review the possibility of venlafaxine withdrawal and some key factors that lead me to this assessment. A 59-year-old patient presents to your pharmacy seeking a refill for her Klonopin prescription and to purchase a pill organizer for herself. Upon discussing with her, she reports a slight fever, chills, and fatigue […] The post Venlafaxine Withdrawal – Case Study appeared first on Med Ed 101.
52
52
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
363 
Let's personalize your content